Same – Day NGS Cancer Testing, New Liquid Bx, DNA/RNA Combos Among Developments at AMP 2019

/0 Comments/by Bruce Carlson

Molecular vendors met in Baltimore at the Association for Molecular Pathology meeting in Baltimore Wednesday for pre-convention corporate workshops and presentations. Not surprisingly, some news was made. Several vendors presented new solutions to chip away at result times. Thermo Fisher Scientific launched its Ion Torrent Genexus System, an integrated next-generation sequencing (NGS) platform featuring an […]

Read more

Major Molecular Diagnostic Vendors Announce Workshops for AMP

/by Bruce Carlson

As molecular pathologists, pharmaceutical companies and in vitro diagnostic vendors gather in Baltimore MD for the upcoming Association for Molecular Pathology (AMP) in Baltimore, MD. corporate workshops have been announced.  The workshops indicate the direction the industry is going, with new molecular technologies such as mass spec and NGS replacing traditional ones in some cases.   Roche, Abbott […]

Read more

Molecular Diagnostics Market Now Larger Than the Economies of 50 Nations, per New Report

/by Bruce Carlson

As molecular testing vendors meet this month in Baltimore for the Association for Molecular Pathology (AMP) 2019 meeting, market research firm Kalorama Information, specialist in in vitro diagnostics markets, estimates that tests aiding the detection and treatment of disease at the molecular level are the fastest-growing test category in all diagnostics. And the firm says […]

Read more

Kalorama, Science and Medicine Group Will Be at AMP 2019

/by Bruce Carlson

Kalorama Information, along with representatives from parent company Science and Medicine Group, will be present at the Association for Molecular Pathology (AMP) meeting in Baltimore Maryland.  We will be covering the meeting for Lab Pulse.com, Kalorama Information and Instrument Business Outlook. Seminars of particular interest to Kalorama Information: Practical Approaches to Centralizing (or Decentralizing) Molecular […]

Read more

IVD Procedures Reach 68 Billion

/by Bruce Carlson

The global volume of in vitro diagnostic (IVD) procedures has reached over 68 billion and is forecast to increase 3.4% annually to 81.0 billion in 2024, according to Kalorama’s new report on procedure volumes. These statistics are important for business planning, particularly for new products. The same timeframe will see worldwide sales of IVD products […]

Read more

Qiagen/Illumina Deal: “positive development for clinical NGS”

/by Bruce Carlson

This is a positive development for next-generation sequencing’s clinical future, not only in diagnostic assessment of disease but also in therapy selection. But this is still about future development, and we’ll watch the products that the collaboration produces. We’ll also watch what the competition does — partnerships oft beget other partnerships.” KALORAMA as quoted in […]

Read more

Introducing: The Kalorama Clinical Masterfile

/by Bruce Carlson

Announcing a new product from Kalorama Information, Part of the Science and Medicine Group.  The  Kalorama Clinical Masterfile. For the best business results, clinical diagnostics marketers need knowledge about several elements: What products do my customers currently have? What types of products? Clinical Chemistry, Micro, Molecular, Immunoassays, Hematology? How old are those systems?  Is it […]

Read more

Milestone Reached for Kalorama Information under New Ownership as Part of Science and Medicine Group

/by Bruce Carlson

Kalorama Information, a part of Science and Medicine Group, has announced that it has published its 25th report since the acquisition of the company by Science and Medicine Group. Since November, the firm has reported on food safety testing, infectious disease, Latin American Markets, molecular diagnostics and many other markets. “Experts in sequencing, liquid biopsy, […]

Read more

Red Flags Raised With CLIA Waived Test Growth

/by Bruce Carlson

As reported on LabPulse.com (Sign up at http:www.labpulse.com) — Providers of proficiency testing for CLIA tests are becoming increasingly concerned about the lack of external quality control and oversight of CLIA-waived test kits, as the number of waived kits continues to expand. Some 1,400 waived test kits are now on the market, compared with 30 […]

Read more

Quidel and Abbott Lead in POC Cardiac Markers

/by Bruce Carlson

Quidel is the market leader in point-of-care (POC) cardiac markers, according to a recent report from Kalorama Information. Abbott, Roche and Siemens Healthineers and Response Biomedical also are among the top companies. The findings were reported in Kalorama Information’s latest report, Worldwide Market for Point-of-Care (POC) Diagnostics. Quidel is a market leader in rapid immunoassays and […]

Read more